Listing of Claims

1. (Amended) A method for preventing ~~inhibiting~~ immunoglobulin-induced toxicity in a subject, ~~resulting from immunoglobulin immunotherapy in a subject~~ comprising administering an immunoglobulin molecule to a [[the]] subject, said [[the]] immunoglobulin molecule having a variable region and a constant region, said [[the]] immunoglobulin molecule being modified prior to administration by structurally altering multiple toxicity-associated regions in the CH_2 [[CH2]] domain of said constant region so that immunoglobulin-induced toxicity is inhibited in said subject, wherein said multiple toxicity-associated regions comprise amino acids 231-238 and amino acids 310-331 of said CH_2 domain.

2. (Amended) A method for preventing ~~inhibiting~~ immunoglobulin-induced toxicity in a subject, ~~resulting from immunoglobulin immunotherapy in a subject~~ comprising administering a structurally altered antibody to a [[the]] subject, said [[the]] structurally altered antibody comprising a variable region and a constant region, wherein multiple toxicity-associated regions in the CH_2 [[CH2]] domain of said constant region are [[being]] modified so as to render said [[the]] constant region unable to mediate an antibody dependent cellular cytotoxicity response or activate complement, thereby inhibiting immunoglobulin-induced toxicity, ~~resulting from immunotherapy~~ wherein said multiple toxicity-associated regions comprise amino acids 231-238 and amino acids 310-331 of said CH_2 domain.

Do not entry.

3. (Amended) A method for preventing ~~inhibiting~~ immunoglobulin-induced toxicity in a subject, ~~resulting from immunotherapy in a subject~~ comprising administering an Ig fusion protein to a [[the]] subject, said [[the]] Ig fusion protein having multiple structurally altered toxicity-associated regions in the CH_2 [[CH2]] domain of the constant region of said Ig fusion protein, wherein said multiple structurally altered toxicity-associated regions comprise amino acids 231-238 and amino acids 310-331 of said CH_2 domain.

4. (Amended) A method for preventing ~~inhibiting~~ immunoglobulin-induced toxicity in a subject, ~~resulting from immunotherapy in a subject~~ comprising administering an Ig fusion protein to a [[the]] subject, said [[the]] Ig fusion protein comprising a modified constant region, the modification being a structural alteration in multiple toxicity-associated regions within the CH_2 [[CH2]] domain of said constant region, wherein said multiple toxicity-associated regions comprise amino acids 231-238 and amino acids 310-331 of said CH_2 domain.